Here are relevant reports on : anti-obesity-drugs-market
-
Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030
The global injectable drug delivery market, valued at USD 633.77 billion in 2024, stood at USD 690.23 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of USD 1,034.78 billion by the end of the period. The injectable drug delivery market is driven by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics.
- Published: May 2025
- Price: $ 8150
- TOC Available:
-
Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030
The global neuromodulation market, valued at US$6.26 billion in 2024, stood at US$6.81 billion in 2025 and is projected to advance at a resilient CAGR of 9.4% from 2025 to 2030, culminating in a forecasted valuation of US$10.68 billion by the end of the period. Neuromodulation is increasingly recognized as an effective method for managing chronic conditions and improving patients’ quality of life.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Europe Patient Engagement Solutions Market by Therapy (Chronic [CVD, Obesity], Women's Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing, Education), End User (Hospitals, ASCs, Payers, Patients) - Forecast to 2030
The Europe Patient Engagement Solutions market, valued at USD 6.42 billion in 2024, stood at USD 7.35 billion in 2025 and is projected to advance at a resilient CAGR of 12.7% from 2025 to 2030, culminating in a forecasted valuation of USD 13.37 billion by the end of the period. This development is fueled by the changing trend toward value-based and outcome-oriented care, escalating the need to provide continuous interaction with patients outside of clinical care, and an increasing use of digital front-door solutions (patient portals and virtual assistants).
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Europe Injectable Drug Delivery Market by Product (Device, Self Injection, Formulation, Solution, Emulsions), Formulation Packaging (Ampoules, Bottles), Therapeutic Application (Obesity, Diabetes, Cancer, Psoriasis), Usage Pattern - Forecast to 2031
The Europe injectable drug delivery market, valued at US$166.13 billion in 2025, stood at US$178.87 billion in 2026 and is projected to advance at a resilient CAGR of 7.7% from 2026 to 2031, culminating in a forecasted valuation of US$259.49 billion by the end of the period. The increasing use of biologics, biosimilars, and long-acting injectables is driving market growth. There is an increasing demand for patient-centric delivery systems and self-administration in major healthcare markets.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033
The global GLP-1 analogues market, valued at US$53.74 billion in 2024, stood at US$64.42 billion in 2025 and is projected to advance at a resilient CAGR of 13.0% from 2025 to 2033, culminating in a forecasted valuation of US$170.75 billion by the end of the period. The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players in the GLP-1 agonists market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Metabolism Assays Market Size, Share & Trends by Product (Instruments, Assays Kits), Technology (Colorimetry, Fluorimetry, Spectrometry), Application (Diagnostics (Diabetes, Obesity), Research), End User (Hospitals, Diagnostic Laboratories), & Region - Global Forecast to 2028
The global metabolism assays market, valued at US$1.3B in 2022, is forecasted to grow at a 7.8% CAGR, reaching US$1.4B by 2023 and US$2.1B by 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Patient Engagement Solutions Market by Therapy (Chronic [Obesity, Diabetes], Women’s Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient), Unmet Need, Investment - Forecast to 2030
The Asia Pacific Patient Engagement Solutions market, valued at USD 3.45 billion in 2024, stood at USD 3.97 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of USD 7.48 billion by the end of the period. This growth is driven by the rising demand for patient-centered and personalized care, a rapid expansion of telehealth and remote care frameworks, and more investments in digital healthcare infrastructure within the Asia Pacific region.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031
The US injectable drug delivery market, valued at US$285.81 billion in 2025, stood at US$309.90 billion in 2026 and is projected to advance at a resilient CAGR of 8.5% from 2026 to 2031, culminating in a forecasted valuation of US$465.15 billion by the end of the period. The growth of the veterinary contract manufacturing & research market is driven by the increasing adoption of biologics and long-acting injectables, rising demand for patient-centric and self-administration delivery systems, and the need for advanced formulation, device engineering, and scalable manufacturing capabilities.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1, GPE, CGRP), Therapeutic Area (Nephrology, Gastroenterology, Genetic, CNS, Obesity, Diabetes), Formulation (Tablet, Capsule) - Global Forecast to 2030
The global oral proteins and peptides market, valued at US$8.07 billion in 2024, stood at US$9.31 billion in 2025 and is projected to advance at a resilient CAGR of 16.4% from 2025 to 2030, culminating in a forecasted valuation of US$19.93 billion by the end of the period. This growth is driven by several factors, including the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Autoinjectors Market by Type (Devices, Finished Formulation), Usage (Disposable, Reusable), Actuation Mechanism (Mechanical, Electronic), Therapy (Rheumatoid Arthritis, Obesity, Diabetes), ROA (SC, IM), Volume (< 3ml, > 3ml) - Global Forecast to 2031
The global autoinjectors market, valued at USD 107.60 billion in 2025, stood at USD 127.30 billion in 2026 and is projected to advance at a resilient CAGR of 18.7% from 2026 to 2031, culminating in a forecasted valuation of USD 300.46 billion by the end of the period. Some of the leading companies in the device-only autoinjectors market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). Key players in the finished formulation autoinjectors market include Novo Nordisk (Denmark), AbbVie Inc. (US), and Eli Lilly and Company (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
